LLY Earnings & Financial Statements
Eli Lilly and Company
$1,208.74
+$42.23(+3.62%)
60
Overall
45
Value
66
Tech
71
Quality
Market Cap
$1.10T
Volume
3.15M
52W Range
$783.85 - $1,292.65
Target Price
$1,357.04
LLY earnings and financial statements: Eli Lilly and Company's income statement, balance sheet and cash flow statement, annual and quarterly.
LLY Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $65.18B | $45.04B | $34.12B | $28.54B | $28.32B |
| Cost of revenue | $11.05B | $8.42B | $7.08B | $6.63B | $7.31B |
| Operating income | $26.80B | $13.74B | $6.53B | $7.37B | $7.64B |
| EBITDA | $27.73B | $14.45B | $8.57B | $8.66B | $8.04B |
| Net income | $20.64B | $10.59B | $5.24B | $6.24B | $5.58B |
| EPS (diluted) | $22.95 | $11.71 | $5.80 | $6.90 | $6.12 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $112.48B | $78.72B | $64.01B | $49.49B | $48.81B |
| Total liabilities | $68.56B | $52.90B | $53.14B | $38.71B | $39.65B |
| Shareholders’ equity | $26.54B | $14.27B | $10.77B | $10.65B | $8.98B |
| Cash and equivalents | $7.27B | $3.27B | $2.82B | $2.07B | $3.82B |
| Long-term debt | $40.87B | $28.53B | $18.32B | $14.74B | $15.35B |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $16.81B | $8.82B | $4.24B | $7.59B | $7.37B |
| Capital expenditure | -$7.62B | -$4.46B | -$7.39B | -$2.99B | -$1.98B |
| Free cash flow | $8.97B | $3.76B | $792.50M | $4.60B | $5.39B |
| Dividends paid | $5.38B | $4.68B | $4.07B | $3.54B | $3.09B |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | LLY | $1,208.74 | +3.6% | 3.15M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |